Comment on Spinraza’s flat sales rattle investors but Biogen sees momentum for key rare-disease therapy

Spinraza’s flat sales rattle investors but Biogen sees momentum for key rare-disease therapy

The expensive rare disease therapy Spinraza has quickly become a critical part of Biogen’s performance, but the latest sales figures were sluggish.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News